Fostera® PCV MH Now Offers Increased Duration of Immunity10 January 2017
US - Latest study demonstrates at least 23 weeks DOI against Mycoplasma hyopneumoniae.
With Fostera® PCV MH, swine veterinarians and pork producers now have even longer protection against Mycoplasma hyopneumoniae (M. hyo). A recent study1 reviewed and approved by the United States Department of Agriculture’s (USDA) Center for Veterinary Biologics (CVB) demonstrated the vaccine was effective at mitigating lung lesions caused by M. hyo and demonstrated at least 23 weeks duration of immunity against the pathogen. Fostera PCV MH now is the only combination vaccine to have demonstrated 23 weeks duration of immunity for both M. hyo and porcine circovirus-type 2.
“Demonstrating that our vaccine can help provide growing pigs the longest possible protection from M. hyo is one way we can continually improve the products we offer to our customers,” said Lucina Galina Pantoja, DVM, PhD., Pork Technical Services, Zoetis. “Enzootic pneumonia or mycoplasmal pneumonia caused by M. hyo is a prevalent and costly disease, and vaccination can be one part of an effective, comprehensive approach to controlling M. hyo.”
Fostera PCV MH is labeled for the vaccination of healthy pigs three weeks of age and older as an aid in preventing viremia, lymphoid depletion, and colonization of lymphoid tissue caused by porcine circovirus type 2; and as an aid in reducing PCV2 virus shedding and enzootic pneumonia caused by M. hyopneumoniae. The vaccine is available in 50 and 250 dose presentations.
For more information about managing M. hyo in swine herds, visit Mhyo5step.com.
|ThePigSite News Desk||Read more Zoetis news here|